<DOC>
	<DOCNO>NCT00964171</DOCNO>
	<brief_summary>RATIONALE : Efavirenz may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well efavirenz work second-line therapy treat patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Efavirenz Second-Line Therapy Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy efavirenz second-line monotherapy , term non-morphological progression 2 month , patient metastatic adenocarcinoma pancreas . Secondary - Evaluate non-morphological progression patient 4 month . - Evaluate non-biological progression patient 2 4 month . - Evaluate quality life patient 2 4 month . - Evaluate overall , progression-free , event-free survival patient . - Evaluate tolerability safety profile efavirenz patient . OUTLINE : This multicenter study . Patients receive oral efavirenz daily absence disease progression unacceptable toxicity . Patients complete quality-of-life questionnaire use QLQ-C30 baseline 2 4 month . After completion study therapy patient follow every 2 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas No histological type Radiologically confirm metastatic disease nonirradiated area Measurable disease accord RECIST criterion Must exhaust firstline gemcitabine hydrochloride chemotherapy No CNS metastases PATIENT CHARACTERISTICS : WHO performance status ( PS ) 02 OR Karnofsky PS 70100 % ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Creatinine ≤ 1.25 time upper limit normal Alkaline phosphatase &lt; 5 time normal Bilirubin &lt; 3 time normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Has French Social Security compliance French law relate biomedical research Able comply study treatment followup No severe renal failure No severe hepatic impairment No known hypersensitivity study drug excipients No depression total score ≥ 13 Hospital Anxiety Depression ( HAD ) scale No active diarrhea may affect ability absorb study drug No cancer within past 5 year except carcinoma situ cervix basal cell carcinoma skin No geographical , psychiatric , social , psychological reason would preclude compliance study procedure PRIOR CONCURRENT THERAPY : Recovered prior anticancer therapy More 30 day since prior investigational drug and/or participation clinical trial Prior adjuvant chemotherapy ( oneline ) and/or radiotherapy allow No prior enrollment study No prior treatment act signal transduction pathway No prior yellow fever vaccine No concurrent secondline therapy No concurrent terfenadine , astemizole , cisapride , midazolam , triazolam , pimozide , bepridil , rye alkaloid , voriconazole , St. John wort ( Hypericum perforatum )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>